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Abstract 
High active antiretroviral therapy (HAART) can reduce plasma viremia to levels below the limit of 
detection, leading to adequate immune recovery and clinical stability in most HIV-1-infected patients. 
However, the virus persists in reservoirs, and free virions can be found in the plasma. We report here 
the case of an HIV-infected patient diagnosed in 1999, who exhibited good adherence to medication 
and HAART efficacy after multiple protocol changes. In this study, we describe the clinical features, 
chronological changes in HIV viral load and CD4+ T-cell count, and treatment outcomes of multiple 
combinations of antiretrovirals (ARV).The patient presented cycles of viral load during treatment ranging 
from undetectable, low, and intermediate HIV-1 RNA levels, to levels above the limits of quantification. 
A therapeutic regimen intensified with raltegravir (RAL) promoted constant depletion of HIV viral load 
and an increase in CD4+ T-cells. The report shows that enhanced HAART efficacy using RAL can 
reduce HIV viral load. 
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High active antiretroviral therapy (HAART) has 
been reported to be efficacious in hastening 
immunological recovery and symptomatic 
improvement after antiretroviral therapy (ART). 
Indeed, an overall good immunological response 
is observed, with higher CD4+ T-cell counts, 
temporally and quantitatively. Although ART 
efficacy controls viremia, many factors and 
events may necessitate a change in therapy, 
such as drug toxicity, viral resistance and 
mutation, treatment adherence, cost, and 
medical support [1,2]. 
 
In spite of significant HIV-related morbidity and 
mortality, HAART effectively suppresses, but 
does not eradicate, HIV-1 infection [1]. Low but 
persistent HIV-1 RNA levels can still be detected 
in plasma and cellular reservoirs [3,4] even after 
several years of suppressive HAART, and 
cessation of treatment invariably results in the 
resumption of viral replication.  
 
In addition to the persistence of long-lived, 
latently infected cells, low-level viral replication 
has been proposed as a mechanism that 
maintains HIV-1 during HAART. If complete viral 
replication cycles persist, despite suppressive 
ART, this would lead to a recurrence of cellular 
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infection and a constant replenishment of the 




In this case report, we describe the clinical 
features, chronological changes in HIV viral load 
and CD4+ T-cell count, and treatment outcomes 
associated with multiple combinations of ARV in 
a 46-year-old man. Data collected since 1999, 
the date of diagnosis, were obtained from 
medical records in Public Specialities Clinic. The 
patient received the diagnosis of HIV infection on 
April 1999 with subsequent medical follow-ups at 
an average frequency of three times per year for 
sixteen years. The initial physical examination 
was normal without any sign of chronic disease, 
opportunistic infection, or AIDS-defining 
complications. 
 
The patient began HAART in June 1999 at which 
time his plasma HIV-1 RNA level was 200,000 
copies/mL. The initial ART regimen prescribed 
included didadosine (DDI) + stavudine (d4T), and 
a good therapeutic response was observed, 
including full suppression of HIV plasma viremia 
and a CD4+ T-cell count >500 cells/µL.  
 
During 16 years of treatment from 1999 to 2015, 
virological and immunological responses to 
various combinations of ARV were monitored, 
and multiple changes were made to the HAART 
regimen due to increases in HIV viral load, 
resistance to ARV, and the presence of adverse 
drug reactions (ADR) (Table 1). 
 
In February 2006, when the patient’s plasma HIV 
RNA level was 183,000 copies/mL, genotypic 
HIV-resistance test showed resistance-conferring 
mutations to nucleoside reverse transcriptase 
inhibitor drugs, but not to non-nucleoside reverse 
transcriptase inhibitor or protease inhibitor (PI) 
drugs. Another genotypic HIV-resistance test 
performed in December 2008 showed no drug 
resistance mutations to ARV. 
 
During treatment, the patient presented typical 
signs of ADR: lipodystrophy syndrome, nausea 
and vomiting, headache, dizziness, tremors, 
lower limb arthalgia, myalgia, rashes on the 
limbs, painful nodular erythema, arthritis, and 
nodules with suppuration of varying degrees of 
intensity and duration. 
 
Despite these signs of ADR, five years of an 
HAART drug regimen intensified with raltegravir 
(RAL) promoted a persistent depletion of the HIV 




A major advance in HIV disease treatment 
occurred with the introduction of HAART, which 
is sufficiently potent to cause complete and 
prolonged cessation of viral replication to allow 
reconstitution of the immune system [5,6]. 
Despite this progress, only 40 to 50 % of patients 
in clinical practice are able to achieve maximal 
and durable suppression of the HIV plasma viral 
load, and this outcome is a strong predictor of 
disease control [6]. 
 
In contrast to most chronic conditions, successful 
treatment of HIV infection requires nearly perfect 
adherence to the treatment regimen to reduce 
viral load and prevent the emergence of drug-
resistant variants, which reduce future treatment 
options and can be fatal [7-9]. 
 
Many studies have suggested that even HAART 
is not effective for completely eliminating HIV- 
 
Table 1: Immunological and virological responses to HAART 
 
  HIV viral load 
Regimen (duration of treatment) CD4+ (cells/µL) Copies/mL (10³) log10 
d4T + DDI (37 months) 704 ± 76 (2) 0.70 ± 0.43 (2) 2.8 
AZT + DDI (20 months) 469 ± 38 (5) 13.03 ±16.89 (5) 3.814 
AZT + 3TC + ATV (27 months) 578 ± 129 (2) 36.92 ± 81.66 (2) 3.132 
3TC + LPV/r + TDF (5 months) 369 (1) 183.00 (1) 5.26 
3TC + EFZ + LPV/r + TDF + T20 (18 months) 251 ± 37 (3) 112.21 ± 91.33 (3) 4.755 
AZT + 3TC + LPV/r + TDF (3 months) 215 (1) 415.64 (1) 5.619 
AZT + 3TC + TDF + RTV + FPV(4 months) 119 (1) >500.00 (1) 5.700 
AZT + 3TC + TDF (3 months) 222 (1) 308.14 (1) 5.489 
AZT + 3TC + LPV/r + TDF + SQV (7 months) 129 (1) 258.81 ± 87.87 (2) 5.398 
AZT + 3TC + DRV + RTV + RAL 48 months) 
AZT + 3TC + DRV + RTV + RAL 12 months) 
281 ± 39 (11) 





Data are presented as mean ± SD (n). D4T= stavudine, DDI = didadosine, AZT = zidovudine, 3TC = lamivudine, 
ATV = atazanavir, LPV/r = lopinavir/ritonavir, TDF = tenofovir, T-20 = enfurvitide, RTV = ritonavir, FPV = 
fosamprenavir, SQV = saquinavir, DRV = darunavir, RAL = raltegravir 
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infected cells, and this could result in viral 
spreading via privileged anatomic compartments, 
including various cell populations or tissues[4]. 
Thus, undetectable viral loads and CD4+ T-cell 
count values >400 cells/µL, as observed in our 
patient, indicate the high efficacy of ART. Viral 
load fluctuation can lead to an increase of HIV 
viral load, which can occur as “blips,” defined as 
measurable plasma viral loads (50–1000 
copies/mL) that are immediately preceded and 
followed by viral loads below the detection limit 
[4,5], which was observed in our patient. The 
identification and characterization of HIV-1 
cellular reservoir(s) in effectively treated patients 
(HIV-1 RNA below the limits of quantification) is a 
high priority, and we suggest that this would be 
an important first step towards the development 
of a strategy for virus eradication. 
 
RAL belongs to the class of HIV integrase 
inhibitors, which target a crucial process in the 
life cycle of HIV. HIV-1 integrase catalyzes the 
insertion of the viral DNA into the genome of the 
host cell [9], both in circulating cells and cell 
reservoirs. Therefore, intensification of the drug 
regimen with RAL or other drugs could increase 
the activity of ART and enhance the inhibition of 




Administration of the ART regimen, AZT + 3TC + 
DRV + RTV + RAL, for 5 years suppressed HIV 
viral load to undetectable levels, suggesting that 
intensified therapy with RAL promotes persistent 
reduction of viremia. 
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